Brain Health | Medical XPRT
Articles & Whitepapers
-
FDA Approved ALK Inhibitors for ALK-Positive Non-Small Cell Lung Cancer
Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a relatively rare and dangerous subtype, with patients suffering from a high incidence rate of brain metastases. Statistics show that about 55% of ALK-positive advanced NSCLC patients will develop brain metastases during ...
-
How Is Frontotemporal Dementia Different From Alzheimer`s?
People living with frontotemporal dementia, or FTD, are commonly misdiagnosed with psychiatric disorders or Alzheimer’s disease and other causes of dementia, such as Parkinson’s disease ...
News
-
RTsafe’s core role for the development of German guidelines for a standard, safe and efficient implementation of Single-Isocentric Multi-Focal SRS throughout the country
RTsafe is happy to announce that its PRIME and Pseudopatient 3D phantoms, have been selected by a consortium of high-end German Radiotherapy Institutions – led by the Division of Medical Physics of the Department of Radiation Oncology at the ...
Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders
ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT
Roswell Biotechnologies Forms Scientific Advisory Board
SpinTech CEO Presents STAGE at MedTech Strategist Innovation San Francisco 2021
Equipment & Solutions
-
Showcase
Natural Formulation Developed To Improve Brain Health, Backed By Pre-Clinical Trials
Mentanine®, supported by (cannabidiol “CBD” + IP formula) – molecules bond and synergistically attach to PPAR receptors allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trials. Mentanine® is a natural pure ...
